ABSTRACT
Purpose To compare the CT imaging performance of a carboxybetaine zwitterionic-coated tantalum oxide (TaCZ) nanoparticle CT contrast agent with that of a conventional iodinated contrast agent in a swine model meant to simulate overweight and obese patients. Materials and Methods Four swine were evaluated inside three different-sized adipose-equivalent encasements emulating abdominal girths of 102, 119, and 137 cm. Imaging was performed with a 64-detector row CT scanner at six scan delays after intravenous injection of 240 mg element (Ta or I) per kilogram of body weight of TaCZ or iopromide. For each time point, contrast enhancement of the aorta and liver were measured by using regions of interest. Two readers independently recorded the clarity of vasculature using a five-point Likert scale. Findings were compared by using paired t tests and Wilcoxon signed-rank tests. Results Mean peak enhancement was higher for TaCZ than for iopromide in the aorta (270 HU [σ = 24.5] vs 199 HU [σ = 10.2], P < .001) and liver (61.3 HU [σ = 11.7] vs 45.2 HU [σ = 8], P < .001). Vascular clarity was higher for TaCZ than for iopromide in 63% (132 of 208), 82% (170 of 208), and 86% (178 of 208) of the individual vessels at the 102-, 119-, and 137-cm girths, respectively (P < .01). Arterial clarity scores were higher for TaCZ than for iopromide in 62% (208 of 336) of vessels. Venous clarity scores were higher for TaCZ than for iopromide in 89% (128 of 144) of the veins in the venous phase and in 100% (144 of 144) of veins in the delayed phase (P < .01). No vessel showed higher clarity score with iopromide than with TaCZ. Conclusion An experimental tantalum nanoparticle-based contrast agent showed greater contrast enhancement compared with iopromide in swine models meant to simulate overweight and obese patients. © RSNA, 2018.
Subject(s)
Contrast Media/chemistry , Obesity/diagnostic imaging , Overweight/diagnostic imaging , Oxides/chemistry , Tantalum/chemistry , Tomography, X-Ray Computed/methods , Animals , Contrast Media/administration & dosage , Disease Models, Animal , Female , Injections, Intravenous , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Oxides/administration & dosage , Swine , Tantalum/administration & dosage , Waist CircumferenceABSTRACT
PURPOSE: To evaluate the blood oxygen level-dependent (BOLD) magnetic resonance imaging (MRI) findings in kidneys of patients with diabetic nephropathy. MATERIALS AND METHODS: BOLD MRI of the kidneys (1.5 T, multigradient-recalled-echo sequence with 12 echoes) was performed in 20 patients with diabetic nephropathy (moderate to severe chronic kidney disease: n = 14; mild chronic kidney disease: n = 6), and seven healthy volunteers. The medullary and cortical R2* values were compared between patients with diabetic nephropathy and healthy volunteers using Student's t-tests. RESULTS: The mean medullary R2* values were lower in patients with diabetic nephropathy compared to healthy volunteers (13.8 ± 2.4 sec(-1) vs. 19.3 ± 1.2 sec(-1), P = 0.0002). The cortical R2* values were not significantly different between the two groups (11.1 ± 0.9 sec(-1) vs. 11.5 ± 0.7 sec(-1), P = 0.7). A multiple logistic regression model using patient age, gender, and degree of chronic kidney disease (none, mild, or moderate to severe) as variables showed that the degree of kidney disease was independently associated with a decrease in medullary R2* values (P = 0.005). CONCLUSION: The medullary R2* values were lower in patients with diabetic nephropathy compared to healthy volunteers.
Subject(s)
Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/pathology , Kidney/pathology , Magnetic Resonance Imaging/methods , Oxygen/blood , Aged , Case-Control Studies , Diagnostic Imaging/methods , Female , Glomerular Filtration Rate , Humans , Image Processing, Computer-Assisted , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/pathology , Male , Middle Aged , Oxygen/metabolism , Regression AnalysisABSTRACT
PURPOSE: To retrospectively investigate the effects of furosemide on the visualization of renal medullary hyperattenuation at unenhanced computed tomography (CT). MATERIALS AND METHODS: This retrospective single-institution study was HIPAA compliant and approved by the institutional review board; requirement for informed consent was waived. This study identified 289 consecutive patients (152 men, 137 women; mean age, 59 years) without ureteral obstruction who underwent unenhanced scanning as part of CT urography; of these, 178 patients did not receive intravenous furosemide prior to imaging and 111 did. The presence of renal medullary hyperattenuation, renal stones, and bladder urine attenuation levels were recorded and compared between patients who did not receive furosemide prior to imaging and those who did by using the chi(2) and unpaired Student t tests. A multiple logistic regression model was used to evaluate independent predictors of visualization of renal medullary hyperattenuation. RESULTS: Renal medullary hyperattenuation was seen less commonly in patients who received furosemide (27 of 111, 24%) than in those who did not receive furosemide prior to imaging (79 of 178, 44%, P = .001). Bladder urine attenuation was lower in patients who received furosemide (-0.1 HU) compared with those who did not (6.4 HU, P < .001). A multiple logistic regression model revealed independent associations between the visualization of renal medullary hyperattenuation and the absence of furosemide administration (P = .002), younger age (P < .001), and presence of renal stones (P = .047). CONCLUSION: Furosemide administration prior to unenhanced CT is associated with decreased visualization of renal medullary hyperattenuation.
Subject(s)
Diuretics/administration & dosage , Furosemide/administration & dosage , Hematuria/diagnostic imaging , Kidney Medulla/diagnostic imaging , Tomography, X-Ray Computed/methods , Adolescent , Adult , Aged , Aged, 80 and over , Chi-Square Distribution , Contrast Media , Female , Humans , Iohexol , Logistic Models , Male , Middle Aged , Radiographic Image Interpretation, Computer-Assisted , Retrospective StudiesABSTRACT
BACKGROUND: Preterm infants typically experience heavy phlebotomy losses from frequent laboratory testing in the first few weeks of life. This results in anemia, requiring red blood cell (RBC) transfusions. We recently introduced a bedside point-of-care (POC) blood gas analyzer (iSTAT, Princeton, NJ) that requires a smaller volume of blood to replace conventional Radiometer blood gas and electrolyte analysis used by our neonatal intensive care unit (NICU). The smaller volume of blood required for sampling (100 vs 300-500 microl), provided an opportunity to assess if a decrease in phlebotomy loss occurred and, if so, to determine if this resulted in decreased transfusions administered to extremely low birth weight (ELBW) infants. OBJECTIVE: We hypothesized that the use of the POC iSTAT analyzer that measures pH, PCO(2), PO(2), hemoglobin, hematocrit, serum sodium, serum potassium and ionized calcium would result in a significant decrease in the number and volume of RBC transfusions in the first 2 weeks of life. DESIGN/METHODS: A retrospective chart review was conducted of all inborn premature infants with birth weights less than 1000 g admitted to the NICU that survived for 2 weeks of age during two separate 1-year periods. Blood gas analysis was performed by conventional laboratory methods during the first period (designated Pre-POC testing) and by the iSTAT POC device during the second period (designated post-POC testing). Data collected for individual infants included the number of RBC transfusions, volume of RBCs transfused, and the number and kind of blood testing done. There was no effort to change either the RBC transfusion criteria applied or blood testing practices. RESULTS: The mean (+/-SD) number of RBC transfusions administered in the first 2 weeks after birth was 5.7+/-3.74 (n=46) in the pre-POC testing period to 3.1+/-2.07 (n=34) in the post-POC testing period (p<0.001), a 46% reduction. The mean volume of RBC transfusions decreased by 43% with use of the POC analyzer, that is, from 78.4+/-51.6 ml/kg in the pre-POC testing group to 44.4+/-32.9 ml/kg in the Post-POC testing group (p<0.002). There was no difference between the two periods in the total number of laboratory blood tests done. CONCLUSIONS: Use of a bedside blood gas analyzer is associated with clinically important reductions in RBC transfusions in the ELBW infant during the first two weeks of life.
Subject(s)
Blood Gas Analysis/instrumentation , Blood Volume , Erythrocyte Transfusion/statistics & numerical data , Infant, Very Low Birth Weight/blood , Point-of-Care Systems , Age Factors , Female , Humans , Infant, Newborn , Male , Phlebotomy , Retrospective StudiesABSTRACT
OBJECTIVE: To evaluate the feasibility of dual-energy CT (DECT) for monitoring dynamic changes in the renal corticomedullary sodium gradient in swine. MATERIAL AND METHODS: This study was approved by our Institutional Animal Care and Use Committee. Four water-restricted pigs were CT-scanned at 80 and 140 kVp at baseline and at 5 min intervals for 30 min during saline or furosemide diuresis. The renal cortical and medullary CT numbers were recorded. A DECT basis material decomposition method was used to quantify renal cortical and medullary sodium concentrations and medulla-to-cortex sodium ratios at each time point based on the measured CT numbers. The sodium concentrations and medulla-to-cortex sodium ratios were compared between baseline and at 30 min diuresis using paired Student t-tests. The medulla-to-cortex sodium ratios were considered to reflect the corticomedullary sodium gradient. RESULTS: At baseline prior to saline diuresis, the mean medullary and cortical sodium concentrations were 103.8±8.7 and 65.3±1.7 mmol/l, respectively, corresponding to a medulla-to-cortex sodium ratio of 1.59. At 30 min of saline diuresis, the medullary and cortical sodium concentrations decreased to 72.3±1.0 and 56.0±1.4 mmol/l, respectively, corresponding to a significantly reduced medulla-to-cortex sodium ratio of 1.29 (P<0.05). At baseline prior to furosemide diuresis, the mean medullary and cortical sodium concentrations were 110.5±3.6 and 66.7±4.1 mmol/l, respectively, corresponding to a medulla-to-cortex sodium ratio of 1.66. At 30 min of furosemide diuresis, the medullary and cortical sodium concentrations decreased to 68.5±0.3 and 58.9±4.0 mmol/l, respectively, corresponding to a significantly reduced medulla-to-cortex sodium ratio of 1.16 (P<0.05). One of the 4 pigs developed acute tubular necrosis likely related to prolonged hypoxia during intubation prior to the furosemide diuresis experiment. The medulla-to-cortex sodium ratio for this pig, which was excluded from the mean medulla-to-cortex ratio above, was 1.07 at baseline and 1.15 at 30 min following the administration of furosemide. CONCLUSION: DECT monitoring of dynamic changes in the renal corticomedullary sodium gradient after physiologic challenges is feasible in swine.
Subject(s)
Kidney Cortex Necrosis/diagnostic imaging , Kidney Cortex/diagnostic imaging , Kidney Cortex/metabolism , Sodium/metabolism , Tomography, X-Ray Computed/methods , Animals , Contrast Media/administration & dosage , Diuresis , Feasibility Studies , Furosemide/administration & dosage , Iohexol/administration & dosage , Kidney Medulla/diagnostic imaging , Kidney Medulla/metabolism , Pilot Projects , Radiographic Image Interpretation, Computer-Assisted , SwineABSTRACT
OBJECTIVE: To retrospectively evaluate the rate of malignancy of focal fluorine-18 fluorodeoxyglucose (18F-FDG)-avid lesions without computed tomography (CT) correlate at whole-body positron emission tomography (PET)-CT in oncology patients, because better defining these abnormalities could potentially lead to improved patient management algorithms that rely on PET-CT for detection, staging, and treatment monitoring of malignancies. METHODS: We performed a computer search of all PET-CT studies performed at our institution from 2006 to 2009, and identified 87 studies with findings of focal 18F-FDG-avid lesions without correlate at CT. The rate of malignancy of such lesions was determined by reviewing findings at follow-up imaging or by clinical or histopathological follow-up. Rates of malignancy were categorized and compared by lesion location and by the type of primary malignancy. RESULTS: The most common locations for focal 18F-FDG-avid lesions without CT correlate were: lymph node location (without visible lymph nodes; 27/87), bone (21/87), soft tissue (17/87), liver (9/87), and gastrointestinal tract (8/87). Forty-one percent (36/87) of the focal FDG-avid lesions without CT correlate were malignant (either metastatic disease or a second malignancy) at follow-up (mean follow-up: 5 months, range: 1-25 months). Focal FDG-avid lesions in lymph node location and in bone without CT correlate had higher rates of malignancy (56%, 15/27 and 52%, 11/21, respectively) than lesions in all other locations (26%, 10/39, P=0.028). In 15 of 87 cases, the only significant finding at PET-CT was an FDG-avid lesion without CT correlate. Of those, 53% (8/15) was positive for malignancy. There were no significant differences in the rates of malignancy for the focal FDG-avid lesions without CT correlate when stratified by the type of primary malignancy in this series. CONCLUSION: Focal FDG avid lesions without CT correlate were malignant in 41% of cases in our series of oncology patients. Lesions in lymph node location and in bones had the highest rates of malignancy. Knowledge of the patterns and risk of malignancy of focal FDG-avid lesions without CT correlate in oncology patients may facilitate the management of oncology patients with such lesions on PET-CT, and could lead to an improved interpretation of PET-CT scans by imaging specialists.